Almonty's Buyback Firepower Meets a Softer Tungsten Tape and Lower Analyst Targets

Almonty finds itself caught between two separate uncertainties: where the tungsten market goes from here, and whether Sangdong delivers on schedule. Media reports indicate tungsten has surrendered much of its 2026 rally, while analysts have been marking down their price targets on the stock. The underlying confidence can survive intact even as the valuation turns more cautious — that is the distinction worth holding onto.

It is a different finding from a tidy explanation for a single trading session. The shares posted a daily move of -5.1% yesterday. Tying that decline directly to a particular analyst decision or to the tungsten market would be a stretch. The link works as a valuation backdrop, not as proven cause.

Optimism carries a variable price tag

B. Riley Securities cut its target to US$20 from US$25 on Tuesday while keeping its buy rating. The combination says more than either piece alone: the house did not walk away from its positive view, but it set the expected value lower. A buy recommendation is no fixed price tag — it can travel alongside a more guarded valuation. Watch only the unchanged rating and you miss the cut; watch only the cut and you bury the still-positive stance.

Stifel had already trimmed its target to $21 from $25 on October 20, also keeping the buy. The driver was pushed-back assumptions on deliveries from Sangdong Phase I and Phase II, an adjustment that followed the October 19 investor day. Timing now moves to center stage. The analyst reaction is not just a label for the stock — it is a set of expectations about when shipments actually land, and that is precisely where project progress meets market valuation.

Announcements and execution are different animals

Almonty announced on October 15 that the first commercial tungsten shipment from Sangdong would go out on October 24. An announcement describes a plan; it should not be treated as a completed shipment simply because the intended date has since passed. For investors the sober standard is to keep commodity development, delivery assumptions and actual completed steps in separate boxes. A weaker tungsten market does not automatically explain every price move, and a maintained buy rating does not erase the meaning of a lower target.

Korea is an option, not a progress report

The exchange of views on a Korean listing reported Tuesday is, above all, a strategic option. No confirmed decision has been made. The considerations are understandable, but they deserve little weight in the valuation for now. An additional listing touches the capital-markets footprint first; it does not answer whether Almonty executes its operating plans. Investors should keep that line clear: another strategic possibility is not yet an economic result. The news merits attention, not a leap of faith. Its weight would grow only with concrete decisions and terms. Until then, the potential listing should be treated neither as a done-deal expansion of the exchange presence nor as a substitute for progress at Sangdong.

Buybacks must be judged against the whole picture

Capital deployment is far more tangible. Almonty also cited a bank balance of CAD 1.2 billion. That matters for context: the company is setting a substantial buyback program against a weak tape. The point is to pay closer attention to capital allocation. The key question is not solely whether the company repurchases its own shares, but how that use of capital stacks up next to the operating projects.

An Almonty-commissioned analysis published October 21 put buybacks completed through the end of September at roughly US$48 million. It also described the Phase 2 expansion at Sangdong as ongoing, with completion expected in 2027. Who commissioned the report, and its forward-looking nature, both belong in the assessment. A company-funded analysis is not the same as independent confirmation, and the expected completion remains a future point. The buyback documents capital deployment; it does not by itself prove the mine expansion is being delivered successfully.

Execution remains the yardstick

The latest analyst move fits a differentiated verdict. B. Riley Securities lowered its target to $20 from $25 on Tuesday but held its buy recommendation — no wholesale retreat from the positive view, yet a reminder that a favorable vote can come with reduced expectations. The assumptions on Sangdong delivery timing changed about two weeks ago, and that is important background. Investors should not fixate on the number of supportive capital-markets measures. What counts is whether Almonty meets the operating expectations those valuations rest on.

The verdict is accordingly reserved: the Korean listing option widens the strategic room, while the buyback is a concrete capital decision. Both deserve notice. More weight, however, belongs to hard progress at Sangdong. As long as the valuation rests on expected execution, capital-markets initiatives are a complement to the investment case — not its proof. Almonty's valuation demands more than a choice between optimism and pessimism; what matters is which expectations on price and delivery hold up.